Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial

NCT02992834 Phase 4 UNKNOWN

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma.

Details

Lead sponsor	jiangjingting
Phase	Phase 4
Status	UNKNOWN
Enrolment	10
Start date	2016-12
Completion	2022-01

Conditions

• Lymphoma, B Cell

Interventions

• IL-2 pre-treated CD19 cells
• IL-7/IL-15 pre-treated CD19 cells

Primary outcomes

• overall survival — 5 year

Countries

China